You are here

Dow 30

Johnson & Johnson Slides On Top-Line Miss, Disappointing Drug Sales, Soft Outlook

On the surface, key Dow component Johnson & Johnson reported strong earnings, with EPS of $1.58 coming stronger than the $1.56 consensus expectation, despite revenue of $1.81BN missing consensus of $18.28BN. Among the key notables in the earnings report was the company's announcement it was in a process to evaluate potential strategic options for the Johnson & Johnson Diabetes Care Companies, specifically LifeScan, Animas, and Calibra. Such option  "may include the formation of operating partnerships, joint ventures or strategic alliances, a sale of the businesses."

Shiller Warns US Stock Market 'Trump Effect' "Is Based On Illusion"

Authored by Robert Shiller, originally posted op-ed at The Guardian,

Speculative markets have always been vulnerable to illusion. But seeing the folly in markets provides no clear advantage in forecasting outcomes, because changes in the force of the illusion are difficult to predict.

In the US, two illusions have been important recently in financial markets.

Pages